JNCE - ジョンス・セラピュ―ティクス (Jounce Therapeutics Inc.) ジョンス・セラピュ―ティクス

 JNCEのチャート


 JNCEの企業情報

symbol JNCE
会社名 Jounce Therapeutics Inc (ジョンス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジャウンス・セラピューティックス(Jounce Therapeutics Inc.)は臨床段階の免疫療法会社である。同社は免疫システムが腫瘍を攻撃し、患者に長続きする利益を提供する治療法を開発することにより、癌の治療法を変革することに従事する。同社は、翻訳科学プラットフォームを使用して、最初に腫瘍内の特定の細胞型に焦点を当てて標的の優先順位を付け、適切な治療法に合致するように設計された関連バイオマーカーを特定する。主要製品候補であるJTX-2011は、誘導性T細胞CO刺激薬(ICOS)に結合して活性化するモノクローナル抗体であり、第II相試験中である。   ジョンス・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がん免疫療法の開発に従事する。免疫療法によりがん細胞を攻撃し、患者に長期にわたり効果が出る治療法を開発する。同社プラットフォ―ムによりがん細胞をタ―ゲットにし、バイオマ―カ―を特定し適切な治療を行うことを目標とする。本社所在地はマサチュ―セッツ州ケンブリッジ。   Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
本社所在地 780 Memorial Drive Cambridge MA 02139 USA
代表者氏名 Richard Murray リチャード・マレー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 857-259-3840
設立年月日 40969
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 112人
url www.jouncetx.com
nasdaq_url https://www.nasdaq.com/symbol/jnce
adr_tso
EBITDA EBITDA(百万ドル) -31.61000
終値(lastsale) 6.415
時価総額(marketcap) 209306233.62
時価総額 時価総額(百万ドル) 182.06220
売上高 売上高(百万ドル) 61.63900
企業価値(EV) 企業価値(EV)(百万ドル) -50.64880
当期純利益 当期純利益(百万ドル) -31.15000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jounce Therapeutics Inc revenues decreased 25% to $30.6M. Net loss applicable to common stockholders increased from $3.8M to $17.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Employee compensation R&D increase of 27% to $11.5M (expense) Stock-based Compensation in SGA increase from $839K to $2.3M (expense).

 JNCEのテクニカル分析


 JNCEのニュース

   What's in Store for Jounce (JNCE) This Earnings Season?  2020/02/20 15:31:00 Zacks Investment Research
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
   Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?  2019/12/20 16:30:10 Zacks Investment Research
Is (JNCE) Outperforming Other Medical Stocks This Year?
   Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?  2019/12/05 15:37:00 Zacks Investment Research
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission  2019/12/05 12:14:16 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of strategic options, including a potential sale) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bausch Health Companies Inc (NYSE: BHC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Incyte Corporation (NASDAQ: INCY ) Inspire Medical Systems Inc (NYSE: INSP ) IVERIC bio Inc (NASDAQ: ISEE ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co.
   Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates  2019/08/07 11:55:08 Zacks Investment Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?  2019/12/20 16:30:10 Zacks Investment Research
Is (JNCE) Outperforming Other Medical Stocks This Year?
   Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?  2019/12/05 15:37:00 Zacks Investment Research
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission  2019/12/05 12:14:16 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of strategic options, including a potential sale) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bausch Health Companies Inc (NYSE: BHC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Incyte Corporation (NASDAQ: INCY ) Inspire Medical Systems Inc (NYSE: INSP ) IVERIC bio Inc (NASDAQ: ISEE ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co.
   Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates  2019/08/07 11:55:08 Zacks Investment Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   2 Promising $5 Biotech Stocks to Consider on Recent News  2019/07/29 14:00:00 TheStreet
Jounce Therapeutics (JNCE) and Ocular Therapeutix (OCUL) are two promising biotech stocks selling for less than $5 that each provided investors with positive news morsels last week….BA
   Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?  2019/12/20 16:30:10 Zacks Investment Research
Is (JNCE) Outperforming Other Medical Stocks This Year?
   Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?  2019/12/05 15:37:00 Zacks Investment Research
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
   The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission  2019/12/05 12:14:16 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of strategic options, including a potential sale) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bausch Health Companies Inc (NYSE: BHC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Incyte Corporation (NASDAQ: INCY ) Inspire Medical Systems Inc (NYSE: INSP ) IVERIC bio Inc (NASDAQ: ISEE ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co.
   Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates  2019/08/07 11:55:08 Zacks Investment Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   2 Promising $5 Biotech Stocks to Consider on Recent News  2019/07/29 14:00:00 TheStreet
Jounce Therapeutics (JNCE) and Ocular Therapeutix (OCUL) are two promising biotech stocks selling for less than $5 that each provided investors with positive news morsels last week….BA

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジョンス・セラピュ―ティクス JNCE Jounce Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)